J. Goldman & CO LP Tcr2 Therapeutics Inc. Call Options Transaction History

J. Goldman & CO LP

  • $3.75 Billion
  • Q2 2025

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$13.1 - $20.69 $534,480 - $844,152
-40,800 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$6.51 - $16.85 $265,608 - $687,480
40,800 New
40,800 $627,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email